New scan could spot prostate cancer more accurately

NCT ID NCT05847166

Recruiting now Diagnosis Sponsor: NCBJ Polatom: Narodowe Centrum Badań Jądrowych Polatom Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new radioactive imaging agent called PSMA-T4 to see if it can safely and accurately find prostate cancer tumors. About 80 men with prostate cancer will receive an injection of PSMA-T4 and then have a special scan (SPECT/CT) to detect cancer lesions. The goal is to improve diagnosis and treatment planning by comparing this new method with standard imaging techniques.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

4. Wojskowy Szpital Kliniczny z Polikliniką SP ZOZ
COMPLETED

Wroclaw, Poland, 53-114, Poland
Centralny Szpital Kliniczny Uniwersytetu Medycznego
RECRUITING

Lodz, Poland, 92-216, Poland
Centrum Onkologii im. prof. F. Łukaszczyka
RECRUITING

Bydgoszcz, Poland, 85-796, Poland
GAMMED Centrum Diagnostyczno-Lecznicze
RECRUITING

Warsaw, Poland, 02-351, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.